{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T04:30:23Z","timestamp":1783398623488,"version":"3.54.6"},"reference-count":26,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2019,5,1]],"date-time":"2019-05-01T00:00:00Z","timestamp":1556668800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,5,1]],"date-time":"2019-05-01T00:00:00Z","timestamp":1556668800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jaad.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American Academy of Dermatology"],"published-print":{"date-parts":[[2019,5]]},"DOI":"10.1016\/j.jaad.2018.11.023","type":"journal-article","created":{"date-parts":[[2018,11,17]],"date-time":"2018-11-17T11:35:12Z","timestamp":1542454512000},"page":"1364-1370","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":30,"title":["Association of antinuclear antibody status with clinical features and malignancy risk in adult-onset dermatomyositis"],"prefix":"10.1016","volume":"80","author":[{"given":"Paul M.","family":"Hoesly","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason C.","family":"Sluzevich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anokhi","family":"Jambusaria-Pahlajani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth R.","family":"Lesser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael G.","family":"Heckman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andy","family":"Abril","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"9388","key":"10.1016\/j.jaad.2018.11.023_bib1","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1016\/S0140-6736(03)14368-1","article-title":"Polymyositis and dermatomyositis","volume":"362","author":"Dalakas","year":"2003","journal-title":"Lancet"},{"issue":"10","key":"10.1016\/j.jaad.2018.11.023_bib2","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1136\/jnnp.2008.169375","article-title":"Evaluation and treatment of inflammatory myopathies","volume":"80","author":"Amato","year":"2009","journal-title":"J Neurol Neruosurg Psychiatry"},{"issue":"6","key":"10.1016\/j.jaad.2018.11.023_bib3","first-page":"1140","article-title":"Dermatopolymyositis and other connective tissue diseases: a review of 105 cases","volume":"12","author":"Tymms","year":"1985","journal-title":"J Rheumatol"},{"issue":"1","key":"10.1016\/j.jaad.2018.11.023_bib4","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1001\/archdermatol.2009.328","article-title":"Incidence of dermatomyositis and clinically amyopathic dermatomyositis: a population based study in Olmsted County, Minnesota","volume":"146","author":"Bendewald","year":"2010","journal-title":"Arch Dermatol"},{"issue":"3","key":"10.1016\/j.jaad.2018.11.023_bib5","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1006\/clin.1997.4412","article-title":"Epidemiology and estimated population burden of selected autoimmune diseases in the United States","volume":"84","author":"Jacobson","year":"1997","journal-title":"Clin Immunol Immunopathol"},{"issue":"8","key":"10.1016\/j.jaad.2018.11.023_bib6","doi-asserted-by":"crossref","first-page":"1977","DOI":"10.1007\/s10067-016-3296-8","article-title":"Malignancy in dermatomyositis and polymyositis: analysis of 192 patients","volume":"35","author":"Fang","year":"2016","journal-title":"Clin Rheumatol"},{"issue":"1","key":"10.1016\/j.jaad.2018.11.023_bib7","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1111\/bjd.14227","article-title":"Clinically amyopathic dermatomyositis: clinical features, response to medications and malignancy-associated risk factors in a specific tertiary-care-centre cohort","volume":"174","author":"Galimberti","year":"2016","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2018.11.023_bib8","doi-asserted-by":"crossref","DOI":"10.3899\/jrheum.170544","article-title":"Increased levels of soluble programmed death ligand 1 associated with malignancy in patients with dermatomyositis","author":"Chen","year":"2018","journal-title":"J Rheumatol"},{"key":"10.1016\/j.jaad.2018.11.023_bib9","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1093\/rheumatology\/kep078","article-title":"Myositis-specific autoantibodies: their clinical and pathogenic significance in disease expression","volume":"48","author":"Gunawardena","year":"2009","journal-title":"Rheumatology"},{"issue":"2","key":"10.1016\/j.jaad.2018.11.023_bib10","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1007\/s10067-016-3453-0","article-title":"Myositis-specific autoantibodies and their association with malignancy in Italian patients with polymyositis and dermatomyositis","volume":"36","author":"Ceribelli","year":"2017","journal-title":"Clin Rheumatol"},{"issue":"10","key":"10.1016\/j.jaad.2018.11.023_bib11","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1002\/art.1780271011","article-title":"Multiplicity of antibodies in myositis sera","volume":"27","author":"Reichlin","year":"1984","journal-title":"Arthritis Rheum"},{"issue":"6","key":"10.1016\/j.jaad.2018.11.023_bib12","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1136\/ard.49.6.422-c","article-title":"Low incidence of antinuclear antibodies in dermatomyositis with malignancy","volume":"49","author":"Nishikai","year":"1990","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"10.1016\/j.jaad.2018.11.023_bib13","first-page":"140","article-title":"Analysis for the organ involvement and immunological markers of the patients with dermatomyositis","volume":"42","author":"Li","year":"2010","journal-title":"Beijing Da Xue Xue Bao Yi XXue Ban"},{"key":"10.1016\/j.jaad.2018.11.023_bib14","article-title":"Treatment of clinically amyopathic dermatomyositis in adults: a systematic review","author":"Callander","year":"2016","journal-title":"Br J Dermatol"},{"issue":"6","key":"10.1016\/j.jaad.2018.11.023_bib15","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1056\/NEJM199202063260602","article-title":"Risk of cancer in patients with dermatomyositis or polymyositis. A population-based study","volume":"326","author":"Sigurgeirsson","year":"1992","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.jaad.2018.11.023_bib16","first-page":"9","article-title":"Cancer risk following polymyositis and dermatomyositis: a nationwide cohort study in Denmark","volume":"6","author":"Chow","year":"1995","journal-title":"Cancer Causes Control"},{"key":"10.1016\/j.jaad.2018.11.023_bib17","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1159\/000314634","article-title":"Malignancies in autoimmune rheumatic diseases\u2014a mini-review","volume":"57","author":"Szekanecz","year":"2011","journal-title":"Gerontology"},{"issue":"2","key":"10.1016\/j.jaad.2018.11.023_bib18","doi-asserted-by":"crossref","first-page":"e9639","DOI":"10.1097\/MD.0000000000009639","article-title":"Evidence supports blind screening for internal malignancy in dermatomyositis: data from 2 large US dermatology cohorts","volume":"97","author":"Leatham","year":"2018","journal-title":"Medicine (Baltimore)"},{"issue":"2","key":"10.1016\/j.jaad.2018.11.023_bib19","doi-asserted-by":"crossref","first-page":"R70","DOI":"10.1186\/ar2987","article-title":"Cancer risks of dermatomyositis and polymyositis: a nationwide cohort study in Taiwan","volume":"12","author":"Chen","year":"2010","journal-title":"Arthritis Res Ther"},{"issue":"11","key":"10.1016\/j.jaad.2018.11.023_bib20","doi-asserted-by":"crossref","first-page":"2954","DOI":"10.1002\/art.38093","article-title":"Most patients with cancer-associated dermatomyositis have antibodies to nuclear matrix protein NXP-2 or transcription intermediary factor 1 gamma","volume":"65","author":"Fiorentino","year":"2013","journal-title":"Arthritis Rheum"},{"issue":"5","key":"10.1016\/j.jaad.2018.11.023_bib21","doi-asserted-by":"crossref","first-page":"AB170","DOI":"10.1016\/j.jaad.2016.02.668","article-title":"Dermatomyositis and malignancy: a proposal for evidence-based malignancy screening guidelines","volume":"74","author":"Galimberti","year":"2016","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2018.11.023_bib22","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1111\/j.1468-1331.2010.03220.x","article-title":"Screening for tumours in paraneoplastic syndromes: report of an EFNS Task Force","volume":"18","author":"Titulaer","year":"2011","journal-title":"Eur J Neurol"},{"issue":"12","key":"10.1016\/j.jaad.2018.11.023_bib23","doi-asserted-by":"crossref","DOI":"10.1128\/CVI.00270-17","article-title":"Recent approaches to optimize laboratory assessment of antinuclear antibodies","volume":"24","author":"Tebo","year":"2017","journal-title":"Clin Vaccin Immunol"},{"issue":"10","key":"10.1016\/j.jaad.2018.11.023_bib24","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1007\/s10067-011-1766-6","article-title":"Comparison of indirect immunofluorescence and multiplex antinuclear antibody screening in systemic sclerosis","volume":"30","author":"Shanmugam","year":"2011","journal-title":"Clin Rheumatol"},{"issue":"1","key":"10.1016\/j.jaad.2018.11.023_bib25","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1002\/art.30078","article-title":"The antinuclear antibody test: last or lasting gasp?","volume":"63","author":"Fritzler","year":"2011","journal-title":"Arthritis Rheum"},{"issue":"6","key":"10.1016\/j.jaad.2018.11.023_bib26","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1016\/j.autrev.2017.12.008","article-title":"Antinuclear antibodies: is the indirect immunofluorescence still the gold standard or should be replaced by solid phase assays?","volume":"17","author":"Perez","year":"2018","journal-title":"Autoimmun Rev"}],"container-title":["Journal of the American Academy of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S019096221832913X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S019096221832913X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T22:49:45Z","timestamp":1759272585000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S019096221832913X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5]]},"references-count":26,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2019,5]]}},"alternative-id":["S019096221832913X"],"URL":"https:\/\/doi.org\/10.1016\/j.jaad.2018.11.023","relation":{},"ISSN":["0190-9622"],"issn-type":[{"value":"0190-9622","type":"print"}],"subject":[],"published":{"date-parts":[[2019,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Association of antinuclear antibody status with clinical features and malignancy risk in adult-onset dermatomyositis","name":"articletitle","label":"Article Title"},{"value":"Journal of the American Academy of Dermatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaad.2018.11.023","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 by the American Academy of Dermatology, Inc.","name":"copyright","label":"Copyright"}]}}